IO NewsWire

March 15, 2011 07:30 ET

(NASDAQ: UNIS) Issued a $10.50 Price Target by Griffin Securities

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by the IO News Wire.

NEW YORK, NY--(Marketwire - March 15, 2011) - Unilife Corporation (NASDAQ: UNIS) has been issued a revised 12 month price target of $10.50 by Griffin Securities.

The Griffin Securities Report points out that a combination of the company's new manufacturing plant, marketing strategy, and a recent capital raise of over 22 million dollars for the over 200% increase to their target price for the stock in the next 12 months.

Unilife currently has a contract with Sanofi-Aventis for their pre-filled syringes, and has been in talks with over 20 different pharmaceutical companies to utilize the Unilife product with a variety of different injectable drugs.

To read the entire report by Griffin Securities, please visit:

Other active stocks are St. Jude Medical, Inc. (NYSE: STJ), Becton, Dickinson and Co. (NYSE: BDX) and ICU Medical, Inc. (NASDAQ: ICUI)

Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. A third party has hired and paid IO News Wire twelve hundred and ninety five dollars for the publication and circulation of this news release. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. We have no ownership of equity, no representation; do no trading of any kind and send no faxes or emails.

Contact Information